Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy

Figure 1 Receiver operating characteristic curve. A: Receiver operating characteristic (ROC) analysis of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9); B: ROC analysis of CEA, CA19-9, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and systemic immune-inflammation index. CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen; NLR: Neutrophil-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index; ROC: Receiver operating characteristic.

Figure 2 Fraction correct of carcinoembryonic antigen, carbohydrate antigen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index. ¹Fraction correct (FC) overall utility good; ²FC overall utility acceptable; ³FC overall utility poor. CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index.